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It is becoming increasingly clear that immunoactivation, which evolved as a system of host defense against
pathogens, can become dysregulated and promote the pathogenesis of diverse diseases with both known
and unknown etiologies (eg, acquired immune deﬁciency syndrome, age-related macular degeneration,
cancer, as well as aging). Immunoactivation seems to be a “common denominator” or general mechanism of
pathogenesis and may explain the association and similarities in pathology among otherwise unrelated
human diseases. Identiﬁcation of general mechanisms of immunoactivation may lead to the development of
new therapeutic strategies applicable to many diseases even before detailed knowledge of speciﬁc etiology
and pathogenesis may be available.
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All natural sciences evolved from one medieval root,
Philosophia Naturalis, which considered Nature as an
undivided entity and focused on understanding its most
basic principles. Similarly, medicine considered the hu-
man body to be divided at most into 4 humors. With time,
science underwent splitting into more-specialized areas.
More recently, physics and chemistry developed increas-
ingly unifying approaches to explain all the phenomena
within one general theory, whereas medicine was focusing
on speciﬁcs of particular diseases. This led to the pro-
gressive erosion of cross-disciplinary awareness, such
that oncologists may know little about diseases of the
eye, ophthalmologists may be unfamiliar with eye-
unrelated infections, and infectious disease experts may
have only a superﬁcial knowledge of cardiovascularramural Program, Eunice Kennedy-Shriver National
Health and Human Development, National Institutes of
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0.1016/j.amjmed.2014.12.026disease. However, it seems that all these and many other
diseases, including general aging, have one common
driving mechanism, an inappropriate and dysregulated
chronic immunoactivation.
The goal of this article is to emphasize the generality of
this phenomenon, which is still not fully appreciated by the
general biomedical community. Meanwhile, understanding
the role of immunoactivation may explain clustering of
apparently unrelated diseases as well as some similarities in
their pathogenesis and suggests new therapeutic approaches.
Before discussing these general issues, I will ﬁrst deﬁne
the terms and next brieﬂy consider 4 examples of unrelated
diseases to illustrate how immunoactivation may be
involved in the progression of a disease.WHAT IS IMMUNOACTIVATION?
Because the terminology used in the literature is not always
consistent, let us ﬁrst deﬁne the subjects, at least in the
framework of this review.
An encounter with a human pathogen that damages tissues
ﬁrst triggers an innate immune response, which includes
interaction of cell surface pattern recognition receptors with
common pathogen-associated molecular patterns, as well as
other “nonspeciﬁc responses,” such as release of “inﬂamma-
tory” cytokines and of reactive oxygen species, vasodilatation,BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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new proteins (“activation markers”) on cell surfaces, and cell
proliferation. An innate response is followed by the adaptive
immunity response, which may also contribute to inﬂamma-
tion. After the pathogens and their products are eliminated,
most commonly in days or weeks, the immune system returnsCLINICAL SIGNIFICANCE
 Immunoactivation, which evolved as a
system of host defense against patho-
gens, can become dysregulated and
promote the pathogenesis of diverse
diseases with both known and unknown
etiologies and even be an important
factor in general aging.
 Identiﬁcation of general mechanisms of
immunoactivation may lead to the
development of new therapeutic strate-
gies applicable to many diseases even
before detailed knowledge of their spe-
ciﬁc etiology and pathogenesis may be
available.to its basic level.
Sometimes, however, acute
inﬂammation fails to overcome the
damage completely and is trans-
formed into chronic inﬂammation
with continuous upregulation of
various cytokines, cell inﬁltrates,
ﬁbrosis, granuloma, and cell acti-
vation. This response can last from
weeks to years.
The development of sensitive
analytics has revealed that the im-
mune system can remain activated
for years and decades, but below
the level of chronic inﬂammation.
This may happen when the system
does not return to the baseline
completely, but also may develop
de novo as a weak reaction to
harmless foreign antigens. This
state is associated with elevated
levels of some cytokines but not others, and with activation of
some but not of other cell populations; it has been designated
“low-grade inﬂammation,” “para-inﬂammation,”1 or
“immunoactivation,” the term I will use here.IMMUNOACTIVATION AND HIV DISEASE
Unlike many other pathological conditions, HIV disease has
a clear etiologic agent, human immunodeﬁciency virus
(HIV-1). The very name of the virus indicates the nature of
the disease: immunodeﬁciency. The damage caused by
HIV-1 extends beyond the death of a subset of the infected
cells to include death of uninfected cells or of abortively
infected cells,2 followed by the destruction of lymph node
tissue.3 Paradoxically, the driving force of this progressive
immunodeﬁciency is immunoactivation.4
HIV-1 infects and replicates predominantly in activated
CD4þ T cells. The immune system responds to infection by
activating other lymphocytes, including uninfected CD4þ T
cells, thus creating new targets for the virus. This vicious
cycle is facilitated by coinfections with other pathogens,
such as cytomegalovirus (CMV) and other herpesviruses
that are activated in HIV-1einfected individuals, as well by
translocation of bacteria through the damaged gut mucosa,5
further activating the immune system. Unable to eliminate
HIV, the immune system becomes chronically activated,
further facilitating HIV infection. Interestingly, some mi-
crobes that can reduce immune activation (eg, human
pegivirus [GB-virus C]) improve survival of HIV-1einfected
patients.6Immunoactivation during HIV infection is evident from
diverse immune system parameters, including activation
phenotypes of cells, upregulation of selected cytokines7 and
of C reactive protein, activation of matrix metalloproteinase,
and deposition of collagen, which destroys lymph node
cytoarchitecture (reviewed in8). It is immune activation ratherthan HIV-1 load that is a reliable
predictor of disease progression.9
HIV-1etriggered immunoacti-
vation can continue for years, even
after replication of the virus is
suppressed, leading to various
diseases and premature aging.IMMUNOACTIVATION AND
ATHEROSCLEROSIS
Atherosclerosis, the process that
leads to formation of atheroscle-
rotic plaques, is the major cause of
various cardiovascular diseases.
Evidence collected over more than
150 years supports the notion that
activation of the immune system
plays a major role in atheroscle-
rosis (reviewed in10-12). Immune
cells, in particular T lymphocytesand macrophages, but also B lymphocytes, dendritic cells,
and mast cells, are found in large quantities in atheroscle-
rotic plaques. In plaques, both T cells and macrophages are
activated and produce proinﬂammatory cytokines, such as
interferon g and tumor necrosis factor, as well as various
extracellular vesicles13 that also can contribute to cell acti-
vation and facilitate cytokine release. Although plaque T
cells are blood-borne, in plaques they are much more acti-
vated than in blood,14 indicating the presence of local an-
tigens, as is also evident from the clonal expansion in the
early lesions of apolipoprotein Eeknockout mice.15 The
nature of potential antigens in plaques has been debated for
decades, and their list includes oxidized low-density lipo-
proteins, heat shock proteins, and debris of decomposed
cells, as well as various infectious agents.16 Not only local
but also systemic immunoactivation constitutes a strong
proatherosclerotic factor: for example, in autoimmune dis-
eases such as rheumatoid arthritis and systemic lupus ery-
thematosus17 or in end-stage renal disease.18 In conclusion,
although immunoactivation does not seem to be a cause of
atherogenesis, it constitutes an important driver of disease
progression from its initiation to thrombotic complications.IMMUNOACTIVATION AND CANCER
It was generally accepted until approximately 2 decades ago
that the immune system is antitumorigenic, rapidly recog-
nizing and eliminating continually evolving cancer cells
(immuno-surveillance). Fortunately, the immune system
only rarely fails to recognize and destroy the tumor cells,
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tumor, as evidenced by the abundance of immune cells in
solid tumors. Therefore, it was assumed that a rational anti-
cancer strategy would be to facilitate immune system acti-
vation, for example by introducing anticancer vaccines or by
targeting negative regulators of immune system activation
(eg, cytotoxic T lymphocyte-associated protein 4 and pro-
grammed cell death protein 1).
Although an antitumorigenic role for the immune system
is still widely accepted, the contemporary view has become
more nuanced with the appreciation, through increasing
evidence, that the immune system also plays a strong pro-
tumorigenic role.19 Indeed, the risk of tumor formation in
some tissues is signiﬁcantly increased by local inﬂamma-
tion, for example mastitis in the case of breast cancer or
ulcerative colitis in the case of colon cancer.
During the last decade it has become evident that the
immune system can promote tumors in different ways
(reviewed by Grivennikov et al19). First, the very same
lymphocytes and macrophages that inﬁltrate most of the
solid tumors secrete various cytokines that stimulate
growth and inhibit apoptosis of premalignant and tumor
cells. Some of these cytokines work through the activation
of nuclear factor k-light-chain-enhancer of activated B cells
(NF-kB) and signal transducer and activator of transcription
3 (STAT3),19 which are required for expression of several
tumorogenic genes and of antiapoptotic genes such as
Bcl-XL and Bcl-2. Second, immune activation can create a
microenvironment favorable for seeding and local prolifer-
ation of cancer cells. Third, local immunoactivation pro-
motes tumor angiogenesis, without which solid tumor
growth is limited by the diffusion of nutrients. Inactivation
in mice of NF-kB and STAT-3, the key enzymes that in-
ﬂammatory signals activate in the angiogenesis pathway,
results in suppression of angiogenesis and of tumor
growth.20
In conclusion, although immunoactivation may not
initiate cell transformation, it is critical for modulating the
development of cancer through integration and balance of
antitumorigenic with protumorigenic effects.IMMUNOACTIVATION AND AGE-RELATED
MACULAR DEGENERATION
Age-related macular degeneration (AMD), a progressive
and irreversible loss of central vision caused by lesions and
neovascularization of the retina, results in the death of
macular retinal cells. The precise contribution of pro- and
anti-inﬂammatory mediators to AMD is the subject of
intense debate.
The retina is a highly metabolically active tissue with
formation and turnover of various antigenic products of
tissue metabolism. The immune status of a normal eye is
characterized by low activation and an abundance of regu-
latory T cells that suppress activation. When normal intra-
ocular immunosuppressive mechanisms fail to function
properly in the eyes of AMD patients,21,22 the immunogenicproducts accumulated in the eyes may induce a local immune
response, with accumulation of activated immune cells that
secrete inﬂammatory cytokines. Furthermore, autoantibodies
against the products of retinal metabolism activate the
complement system, creating complement-mediated dam-
age23 accompanied by activation of immune cells.
Finally, like other diseases in which immunoactivation
plays a role, AMD is associated not only with local but also
with systemic immunoactivation. In the serum of AMD
patients there is a signiﬁcant increase of interleukin-22,24
which is also expressed in other chronic inﬂammatory
conditions, including psoriasis and rheumatoid arthritis,
where its up-regulation often correlates with increased dis-
ease activity. Also up-regulated is interleukin-17,24 a
proinﬂammatory cytokine that controls extracellular patho-
gens and induces matrix destruction and neovascularization.
Thus, although it remains unclear what triggers AMD,
immunoactivation seems to play a critical role in its
progression.IMMUNOACTIVATION AS A COMMON
DENOMINATOR OF HUMAN PATHOLOGIES?
These few examples superﬁcially described above illustrate that
highly diverse human diseases may have one common feature,
immunoactivation. This may be the basis for the association
between apparently unrelated pathologies. For example,
immunoactivation may link rheumatoid arthritis,25 type 2 dia-
betes,26 or end-stage renal disease18 to atherosclerosis.
It is possible that immunoactivation caused by irritation
of the airway by cigarette smoke may explain why smoking
is a common risk factor not only in cancer of the lung, where
the products of smoking are deposited, but also in many
apparently unrelated pathologies: cardiovascular diseases,
pre-eclampsia, type 2 diabetes, and others.
Additionally, the well-known link of stress to cardio-
vascular disease seems to involve immunoactivation, as
suggested earlier (see Dhabhar27) and was evidenced by a
recently described stress-induced activation of haemopoetic
stem cells and release of high numbers of neutrophils,
monocytes, and lymphocytes into blood.28
Not only the links between apparently unrelated diseases
but also similarities in the pathogenic details may be
explained in the framework of immunoactivation. For
example, as mentioned above, induction of angiogenesis is
typical for solid tumors. Similarly, abnormal angiogenesis,
albeit of leaky vessels, is the main feature of the wet form of
AMD. In an apparent recognition of this similarity, the same
angiogenesis inhibitors are currently used in treatment of
AMD and of some solid tumors.
In addition, rheumatoid arthritis is associated with high
levels of active metalloproteinases as well as of other
collagen-degrading enzymes. Metalloproteinase was re-
ported to be increased in aortas of stressed mice.28 An in-
crease in metalloproteinases may lead to instability and
collapse of atherosclerotic plaques in atherosclerosis. Acti-
vation of metalloproteinases is involved in cancer cell
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cytoarchitecture in HIV-1einfected patients. Similarly,
activation of metalloproteinases leads to liver ﬁbrosis in the
chronic phase of hepatitis B virus infection, characterized by
immunoactivation. Thus, immunoactivation, which is com-
mon to all these human diseases, is associated with an
abnormal activation of the same enzymes, which leads to
pathologies, albeit speciﬁc for each disease.
Immunoactivation can be triggered in healthy individuals
by endogenous agents (eg, microbiota) or by invasion of
low-pathogenic viruses or bacteria. This may predispose to
various diseases that may not progress otherwise.
The important role of immunoactivation in various dis-
eases makes it a potential target for therapy. Successful at-
tempts to use various immune suppressants have been
undertaken in HIV disease, in AMD, in diabetes, and in
atherosclerosis. Moreover, some approved drugs with
known mechanisms of action have been found to have a
general anti-immunoactivation property, which may explain
unexpected treatment effects. For example, statins, which
were introduced for cholesterol-lowering therapy in
atherosclerosis, have been found to suppress immunoacti-
vation and are now prescribed as prophylaxis for cardio-
vascular disease as well as for patients with type 2 diabetes.
Aging may also be mediated by immunoactivation, as best
illustrated in HIV disease. Many physiologic aspects of HIV-
1einfected individuals resemble those that in uninfected
individuals are associated with aging.29 Initially, they were
ascribed to ongoing HIV-1 replication. However, as a result
of efﬁcient anti-HIV therapy many HIV-infected patients
have now been living without detectable presence of HIV
for approximately 2 decades. Nonetheless, these patients
acquire various diseases typical of aging (including cancer,
atherosclerosis, arthritis, and general fragility) approximatelyFigure 1 Immunoactivation hypothesis. Human
agents: viruses, bacteria, parasites, or unknown
human organism. However, disease progression
vation, which is largely similar for all of them. T
same agents or may have been developed before15 years earlier than a control group.9 The immune systems
of these patients are more activated than those of the
controls.9
The early appearance of age-related diseases in HIV-
infected but successfully treated individuals conﬁrms the
role of immunoactivation in these diseases but also consti-
tutes another piece of evidence regarding the role of immu-
noactiavtion in general aging. Additionally, premature aging
has been linked to immunoactivation in rheumatoid arthritis30
and implicated in aging in a Swedish cohort of aged in-
dividuals (85þ years old, with some of them reaching 100).31
As with other cases of immune activation, in HIV-
infected patients it is not clear what supports immunoacti-
vation for many years after HIV-1 is fully suppressed. One of
the candidates is CMV, a common human herpesvirus that
remains reactivated at a low level even years after HIV-1 has
been suppressed.32,33 Interestingly, CMV also was shown to
be a negative factor in the Swedish cohort. Also, CMV has
been suggested as a driving force in cardiovascular dis-
eases,34 however, this association remains controversial.16
The importance of CMV for the human immune system
seems to be underappreciated, because although humans
encounter hundreds of pathogens throughout their life, at an
advanced age a disproportionally high fraction of T lym-
phocytes is speciﬁc for this virus. The clonal expansion of
CMV-speciﬁc T cells with age may shrink the repertoire of
other T cells, thus contributing to increased susceptibility to
various infections that become chronic, triggering persistent
immunoactivation.CONCLUDING REMARKS
The idea that immunoactivation contributes to pathoge-
nesis and disease progression (the “immunoactivationdiseases are triggered by various etiologic
factors causing speciﬁc pathologies in the
also requires a second trigger, immunoacti-
his immunoactivation can be caused by the
and independently of the etiological agent.
566 The American Journal of Medicine, Vol 128, No 6, June 2015hypothesis”) is not new. At different times it was introduced
in various ﬁelds of medicine. For example, with regard to
atherosclerosis it can be traced to Rudolf Virchow in the
19th century, whereas with regard to type 2 diabetes it was
introduced in the early 1990s. However, in most cases the
concept of damaging immunoactivation remained conﬁned
to the ﬁeld of research where it was formulated. Now it is
becoming clear that the immunoactivation hypothesis is
applicable generally.
It is known that many important biological processes
require 2 signals to progress. It seems that for various dis-
eases, immunoactivation is one of the signals (Figure 1).
For example, although HIV-1 is the primary etiologic
agent of the acquired immune deﬁciency syndrome (AIDS),
it is immunoactivation that makes the disease progress to
immunodeﬁciency. Studies of sooty mangabeys have shown
that simian immunodeﬁciency virus (SIV) infection is not
accompanied by immunoactivation, and the infection leaves
the animals healthy, whereas SIV infection of macaques that
is accompanied by immunoactivation leads to AIDS-related
disease.35 Immunoactivation may play a similar role in
diseases for which primary etiologic agents are not known,
such as atherosclerosis or cancer.
Nowadays, immunoactivation is becoming a new thera-
peutic target leading to new therapeutic approaches based on
anti-immunoactivation strategies.ACKNOWLEDGMENT
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